Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14083 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Morad Mohrez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Chemistry and Laboratory Medicine, Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Peripheral Blood Stem Cells, Sickle Cell Trait. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, EuduraCT No: 2018-002652-33.
Abstract (Originalsprache)
Objectives
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCD and bone marrow from an HLA‐matched sibling is currently the standard of care. Haploidentical HSCT from a family donor with a TCR αβ/CD19 depleted graft (T‐haplo) is an increasingly successful alternative, which requires the generation of G‐CSF stimulated peripheral stem cell (PBSC) from haploidentical relatives. These sickle cell trait (SCT) donors reported to develop SCD‐related complications in conditions of severe stress.
Methods
In this retrospective analysis, we compared the safety and efficacy of PBSC mobilization with a G‐CSF intensified mobilization regimen in SCT donors with a conventional G‐CSF mobilization regimen in healthy donors.
Results
The reported adverse events were similar during intensified G‐CSF mobilization, apheresis, and shortly after stem cell apheresis in SCT and control donors. In SCT and control donors, we were able to mobilize high yields of CD34 + stem cells and the harvested CD34 + cell count was comparable with control donors.
Conclusions
Peripheral stem cell mobilization using an intensified G‐CSF regimen is safe, and well tolerated among SCT donors. SCT donors are a valid alternative for collection of peripheral CD34 + stem cells for T‐cell‐depleted haploidentical stem cell transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Clinical Chemistry and Laboratory Medicine, Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany.
- Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Children's Hospital Regensburg, Regensburg, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- EuduraCT No: 2018-002652-33
Zitieren
APA
Mohrez, M., Troeger, A., Kleinschmidt, K., Alali, T. H., Jakob, M., Brosig, A., Hähnel, V., Kietz, S., Offner, R., Burkhardt, R., Corbacioglu, S., Ahrens, N., & Foell, J. (2023). Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen. European Journal of Haematology. https://doi.org/10.1111/ejh.14083
Vancouver
Mohrez M, Troeger A, Kleinschmidt K, Alali TH, Jakob M, Brosig A, et al. Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen. European Journal of Haematology. 2023. doi:10.1111/ejh.14083
BibTeX
@article{Mohrez2023,
author = {Mohrez, Morad and Troeger, Anja and Kleinschmidt, Katharina and Alali, Tarek Hanafee and Jakob, Marcus and Brosig, Andreas and Hähnel, Viola and Kietz, Silke and Offner, Robert and Burkhardt, Ralph and Corbacioglu, Selim and Ahrens, Norbert and Foell, Juergen},
title = {Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14083}
}
EUVIMED